- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00749099
Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)
092206: Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum) From PANCRECARB® (Pancrelipase), Delayed Release Capsules, Buffered and Enteric-Coated Microspheres
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented chronic pancreatitis, alcohol induced chronic pancreatitis or cystic fibrosis
- Documented pancreatic enzyme insufficiency as determined by spot fecal elastase-1 <75 mcg/g stool at the time of inclusion in the study
- Required daily exogenous enzyme supplementation with commercially available pancreatic enzymes
- > 18 years of age
- Male and female subjects qualify
- Able to swallow capsules
- Clinically stable with no evidence of an acute medical condition
- History of steatorrhea
Exclusion Criteria:
- History of fibrosing colonopathy in CF subjects
- Current diagnosis or a history of distal intestinal obstruction syndrome (DIOS) in the past 4 months
- Known contraindication, sensitivity or hypersensitivity to porcine pancreatic enzymes
- Active liver disease
- ALT or AST >3 times the upper limit of normal
- Bilirubin >3 times the upper limit of normal
- Acute pancreatitis or acute exacerbation of chronic pancreatitis
- Acute treatment with any systemic (oral or IV) antibiotics two weeks prior to screening
- Subjects on erythromycin unwilling to discontinue the treatment two weeks prior to screening
- Receiving treatment with antacids or H2 receptor blockers or proton pump inhibitors and unable to discontinue these treatments prior to day 1
- Inability to cooperate with or non-compliant with required study procedures
- Pregnant, breast feeding
- Current daily prescribed scheduled use of narcotics (patients requiring PRN use of narcotics are not excluded)
- Poorly controlled diabetes
- A medical condition which the investigator deems significant enough to interfere with the ability of the subject to participate in the intubation study or interfering with assessment or enzyme bioavailability
- Stomach pH > 4
- Small bowel disease (i.e. celiac disease)
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Phase I
All subject participate in Phase I
|
5 capsules of a placebo drug (Phase I) with a standardized Lundh meal. Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each). |
Active Comparator: Phase II
All subject participate in Phase II
|
The test drug (PANCRECARB® [pancrelipase] - Phase II) with a standardized Lundh meal. Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evidence of the bioavailability of lipase, amylase and protease in the upper intestine from exogenously administered PANCRECARB® (pancrelipase), when taken with a Lundh test meal.
Time Frame: 4 hours post administration of PANCRECARB® and or Placebo
|
4 hours post administration of PANCRECARB® and or Placebo
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DCI092206
- IRB #14687
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exocrine Pancreatic Insufficiency
-
Changhai HospitalPeking Union Medical College Hospital; Xuanwu Hospital, BeijingCompleted
-
Solvay PharmaceuticalsTerminatedPancreatic Exocrine Insufficiency Due to Chronic PancreatitisCzech Republic, Denmark, Hungary, Latvia, Poland, Russian Federation, Sweden
-
AbbottCompletedPancreatic Exocrine Insufficiency, Chronic Pancreatitis, PancreatectomyJapan
-
Abbott ProductsDatamapCompletedPancreatic InsufficiencyIndia
-
Ohio State UniversityAbbVieActive, not recruiting
-
Ruijin HospitalRecruitingPancreatic Exocrine Insufficiency | Pancreaticoduodenectomy | Pancreatic Enzyme Replacement TherapyChina
-
Federal Research and Clinical Center of Physical-Chemical...Moscow State University of Medicine and DentistryCompletedChronic Pancreatitis | Pancreatic Exocrine InsufficiencyRussian Federation
-
Solvay PharmaceuticalsCompletedChronic Pancreatitis | Pancreatic Exocrine Insufficiency | PancreatectomyUnited States, Bulgaria, Poland, Puerto Rico, Russian Federation, Serbia, South Africa, Ukraine
-
Assiut UniversityNot yet recruitingPancreatic Exocrine Insufficiency
-
Azidus BrasilUnknown
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States